The biotech firm projects direct-to-consumer and CDMO revenue growth while targeting fragrance production by late 2027.
BioHarvest Sciences outlined 2026 revenue targets of $38M-$42M from direct-to-consumer sales and $12M-$14M from contract development and manufacturing operations. The company also aims to begin fragrance production in the second half of 2027.
First-quarter 2026 revenue rose 8% year-over-year to $8.5 million, up from $7.9 million in the same period last year. The increase reflects ongoing expansion in its core business segments.
Management highlighted progress toward scaling operations, though no immediate market reaction was disclosed.